Last reviewed · How we verify

NCT04958525

Minimally Invasive Treatment of Hypertensive Basal Ganglia Hemorrhage by Transfrontal Keyhole Neuroendoscopy

Status unknown Last updated 12 July 2021
What this trial tests

trial testing Keyhole neuroendoscopic transfrontal ultrasound-guided hematoma removal in Basal Ganglia Hemorrhage in 52 participants. Status unknown.

Timeline
1 February 2021
Primary endpoint
1 June 2022
1 July 2023

Quick facts

Lead sponsorPeking University Third Hospital
StatusStatus unknown
Study typeOBSERVATIONAL
Enrollment52
Start date1 February 2021
Primary completion1 June 2022
Estimated completion1 July 2023
Sites1 location across China

Drugs / interventions tested

Conditions studied

Sponsor

Peking University Third Hospital

Who can join

Adults 30 to 70, any sex, with Basal Ganglia Hemorrhage. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

To compare the prognosis of patients with hypertensive intracerebral hemorrhage treated by two different surgical methods, and to clarify the therapeutic effect of minimally invasive surgery, so as to find a better surgical method that can reduce surgical trauma and mortality and improve the prognosis of patients

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Basal Ganglia Hemorrhage

Currently open trials in the same condition.

Other Peking University Third Hospital trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04958525.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing